Vir Biotechnology, Inc.
Financials
Valuation Metrics
Vir Biotechnology, Inc.'s Market Cap is $1.86B. At end of 2025 it was $840M. Ranked #1989 of 3,116 in US market (top 64%), #751 of 1,472 on NASDAQ (top 51%), #140 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 53%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.86B | US#1,989/3,116 Sec#140/265 |
| Revenue | $303M | US#2,425/3,116 Sec#97/265 |
| Net Income | $-252M | US—/3,116 Sec—/265 |
| Total Assets | $1.21B | US#2,378/3,116 Sec#84/265 |
| Net Assets | $982M | US#1,767/3,116 Sec#66/265 |
| Employees | 367 | US#2,355/3,116 Sec#101/265 |
| Value | ||
| P/B | 1.89x | US#1,271/3,116 Sec#59/265 |
| P/S | 6.13x | US#2,478/3,116 Sec#93/265 |
| FCF Yield | -17.84% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -25.62% | US#2,528/3,116 Sec#108/265 |
| ROA | -20.72% | US#2,797/3,116 Sec#132/265 |
| Op. Margin | -88.97% | US#2,700/3,116 Sec#119/265 |
| Revenue Growth | 1495.93% | US#13/3,116 Sec#8/265 |
| Financial Health | ||
| Debt Ratio | 23.65% | US#263/3,116 Sec#87/265 |
| Total Debt | $93M | US#2,447/3,116 Sec#124/265 |
| FCF | $-332M | US#2,860/3,116 Sec#236/265 |
| Cash | $279M | US#1,469/3,116 Sec#85/265 |
| Current Ratio | 6.04x | US#386/3,116 Sec#121/265 |
| Performance | ||
| 1Y Return | 84.90% | US#167/3,116 Sec#44/265 |
| 1M Return | -1.34% | US#707/3,116 Sec#49/265 |
| From 52W High | -9.60% | US#355/3,116 Sec#30/265 |
| 1Y MDD | -25.61% | US#993/3,116 Sec#43/265 |
| Trading | ||
| Volume | 1,166,353 shares | US#1,257/3,116 Sec#123/265 |
| Trading Value | $13M | US#2,049/3,116 Sec#159/265 |
| Per Share | ||
| EPS | $-1.49 | US—/3,116 Sec—/265 |
| BPS | $5.83 | US#2,208/3,116 Sec#116/265 |
Company Info
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.